Technology | CT Angiography (CTA) | June 16, 2017

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Visipaque is the first FDA-approved contrast agent indicated for non-invasive CCTA procedure 

GE Healthcares imaging agent Visipaque, iodixanol, is now cleared for use with cardiac CT angiography, CCTA

June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s imaging agent Visipaque (iodixanol) Injection. Visipaque 320 mg iodine/mL is an iso-osmolar agent that is now approved for use in coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of adult and pediatric patients 12 years of age or older with suspected coronary artery disease in the United States.

The new CCTA indication allows healthcare practitioners to image the coronary arteries of patients with suspected coronary artery disease (CAD), offering a non-invasive approach to diagnosis. Traditionally, radiologists and cardiologists have utilized invasive coronary angiography (ICA) procedures to diagnose potential CAD in patients, which can be costly and result in longer patient hospital stays. With Visipaque’s CCTA label extension, healthcare practitioners now have an FDA-approved contrast agent in CCTA procedures that can be performed as an outpatient procedure when evaluating patients with suspected CAD.
 
“Coronary heart disease is a major cause of death in the United States,” said Matt Budoff, M.D., FACC, director of cardiac CT and professor of medicine, Harbor-UCLA Medical Center, Torrance, Calif. “We are excited about the label extension of Visipaque as the first FDA approved iodinated contrast media for use in CCTA. Having an approved contrast agent for CCTA may facilitate the use of CCTA as a gatekeeper to ICA in patients with mild to moderate coronary artery disease, sparing patients from a more invasive procedure and long recovery times.”

Label extension approval for Visipaque 320 mg Iodine/mL for CCTA was evaluated in two prospective, multicenter clinical studies in a total of 1,106 adult patients. Data from the two studies showed that Visipaque has a 99 percent negative predictive value in the diagnosis of CAD (study 1: sensitivity (76-89 percent), specificity (84-89 percent); study 2: sensitivity (95 percent), specificity (87 percent))[1]. Visipaque’s label extension further enhances GE Healthcare’s cardiology portfolio, joining, Myoview, Adreview, and the recently announced distribution rights for Rapiscan outside the U.S. and Canada.

For more information: www3.gehealthcare.com/en/products/categories/contrast_media/visipaque

Related Content

Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
News | PET-CT | June 10, 2021
June 10, 2021 — Bringing the power of...
Cina Chest is part of Avicenna’s CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-Marked solution that supports the detection and triage of stroke and neurovascular emergencies.
News | Artificial Intelligence | June 03, 2021
June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced
An example of how spectral CT can help aid diagnosis in a pancreatic CT which may have a small lesion, but it is difficult to see. The dual-energy imaging clearly shows a lesion. This is example is from the Philips Spectral CT 7500 system.

An example of how spectral CT can help aid diagnosis in a pancreatic CT which may have a small lesion, but it is difficult to see. The dual-energy imaging clearly shows a lesion. This is example is from the Philips Spectral CT 7500 system.

Feature | Computed Tomography (CT) | May 27, 2021 | By Dave Fornell, Editor
May 27, 2021 — Philips Healthcare released a workhorse...
(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastas

(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastasis occurred after 5-month follow-up (not shown). Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | May 18, 2021
May 18, 2021 — According to an open-access Editor's Choice article in ARRS' ...
According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just